Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
40 studies found for:    Open Studies | "Lacrimal Apparatus Diseases"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Lacrimal Apparatus Diseases" (40 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown  Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease
Condition: Dry Eye Syndromes
Interventions: Drug: euphrasia based homeopathic therapy and cyclosporin;   Drug: cyclosporin solution
2 Unknown  Treatment of Dry Eye With Supplements
Condition: Dry Eye Syndromes
Intervention: Dietary Supplement: Vitamac® Tag and Nacht capsules
3 Recruiting Salivary Biomarkers for Sjögren's Syndrome Detection
Condition: Sjögren's Syndrome
Intervention:
4 Recruiting Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
Condition: Chronic Graft-versus-host Disease
Interventions: Drug: R348 Ophthalmic Solution, 0.2%;   Drug: R348 Ophthalmic Solution, 0.5%;   Other: Placebo Ophthalmic Solution
5 Recruiting A Study of Flt3-Ligand Levels in Sjögrens Syndrome
Condition: Sjogrens Syndrome
Intervention:
6 Recruiting Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease
Conditions: Primary Sjogren Syndrome;   Secondary Sjogren Syndrome;   Aqueous Deficient Dry Eye Disease;   Evaporative Dry Eye Disease
Interventions: Drug: Restasis;   Drug: Refresh Endura
7 Recruiting Evaluation of Salivary Gland Dysfunction
Conditions: Sjogren's Syndrome;   Xerostomia
Intervention:
8 Recruiting Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
Conditions: KERATOCONJUNCTIVITIS SICCA;   XEROSTOMIA;   SICCA SYNDROME;   PRIMARY SJOGREN SYNDROME
Interventions: Device: Laser 3R 790nm infrared Ga AIAs;   Device: Laser 3R 790 nm infrared  GaAIAs
9 Not yet recruiting A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Biological: AMG 557/MEDI5872;   Biological: Placebo
10 Recruiting Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Condition: Dry Eye Syndrome
Interventions: Device: T2762;   Device: Vismed®
11 Unknown  Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
Conditions: Sjogren's Syndrome;   Mesenchymal Stem Cells
Intervention: Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)
12 Unknown  Rebamipide for the Treatment of Xerostomia in sjögren Syndrome
Condition: Improving Symptoms of Dry Mouth in Sjőgren's Syndrome
Intervention: Drug: Rebamipide
13 Recruiting The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease
Condition: Dry Eye Disease
Intervention: Dietary Supplement: Omega-3 (Triglyceride form)
14 Recruiting Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes
Condition: Dry Eye Syndromes
Interventions: Drug: Haporine-S;   Drug: Restasis (cyclosporine 0.05%)
15 Recruiting Primary Sjögren Syndrome
Condition: Primary Sjögren's Syndrome
Intervention: Other: skin biopsy
16 Recruiting Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome
Condition: Sjögren's Syndrome
Interventions: Procedure: Sialoendoscopy;   Drug: saline;   Drug: hydrocortisone
17 Recruiting Exercise in Sjogren and Myositis
Conditions: Primary Sjogren´s Syndrome;   Myositis
Intervention: Other: Exercise training
18 Unknown  Green Tea Lozenges for the Management of Dry Mouth
Conditions: Xerostomia;   Sjogren Syndrome;   Dry Mouth
Intervention: Dietary Supplement: Green tea lozenge
19 Recruiting Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
Conditions: Ocular Pain;   Dry Eye Syndrome
Interventions: Drug: SYL1001;   Drug: Placebo
20 Recruiting Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Conditions: Keratoconjunctivitis Sicca;   Dry Eye Disease
Interventions: Drug: OTX-101 0.05%;   Drug: OTX-101 0.09%;   Drug: Vehicle

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years